Navigation Links
MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers
Date:12/2/2010

NOVATO, Calif., Dec. 2, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for BMN 673 for genetically-defined cancers.  The company expects to initiate a Phase 1/2 trial by the first quarter of 2011.

"BMN 673 has been proven to be highly active in mouse xenograft models of human cancer and appears to have superior potency, selectivity, and bioavailability as compared to other products in development," said Hank Fuchs, Chief Medical Officer of BioMarin.  "We are eager to get this trial underway and to identify specific tumor types that are more susceptible to treatment with BMN 673.  We have built a deep R&D pipeline and remain focused on successfully and expeditiously executing on the programs."

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase)
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arbor Pharmaceuticals Completes $34.8 Million Financing
2. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
3. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
4. Apollo Endosurgery Completes First-in-Human Cases With New OverStitch™ Endoscopic Suturing System
5. Boston Scientific Completes Acquisition of Asthmatx
6. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
7. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
8. Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA
9. InfraReDx Completes $21 Million Equity Financing
10. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
11. Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s rapidly changing, highly ... tools are essential for survival. The world is ... desires, preferences, and unmet needs are evolving rapidly. ... across all industries are continually searching for innovative ... adoption of new market research techniques like mobile ...
(Date:12/19/2014)... Somewhere between dropping five pounds and cooking ... Audicus , a next-generation hearing aids company, will ... Hearing loss is the third most common ... is often unaddressed. Forty-eight million Americans have hearing loss, ... mainly due to price. Hearing aids traditionally cost $7,000 ...
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... data from the Collagenase Optimal Reduction of Dupuytren,s ... XIAFLEX ® (collagenase clostridium histolyticum) in the ... palpable cord. This five year observational study was ...
... Company remains committed to speeding innovation to ... boasts 70 potential medicines in clinical development, including 33 in Phases ... potential new medicines in Phase III by the end of 2011, ... as neuroscience, diabetes and oncology, as well as new areas such ...
Cached Medicine Technology:Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 2Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 3Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 4Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 5Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 6Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 7Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 8Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16
(Date:12/22/2014)... Explorys, the leader in big data-driven healthcare transformation, ... Yarrington as Vice President of Operations, Adam Wallace as ... President of Solutions. These new leaders are part of ... to support client demand for the company’s big data ... of its partner network. , Since the company ...
(Date:12/22/2014)... Give a loved one the greatest gift of ... vitality. , For a limited time, HealthiPlus ( https://healthiplus.com/christmas-gift-packages/ ... special Holiday Wellness gift packages at drastically reduced prices ... contains cutting-edge, proven nutritional support for joints, mental functioning ... we age. , Joint Health Plus contains ...
(Date:12/22/2014)... December 22, 2014 The MedTech industry is ... a wholly owned subsidiary of PartnerTech AB of Sweden, is ... recently achieved additional ISO Certification. , All signs point to ... and the likelihood of a repeal of the excise tax ... The industry is anticipating annual growth of 9.3% and PartnerTech ...
(Date:12/22/2014)... New York NY (PRWEB) December 22, 2014 ... reports that a federal panel of judges has granted ... lawsuits in the U.S. District Court, Eastern District ... (JPML) issued an order on December 12 to transfer ... actions–pending in 22 districts to the Louisiana court for ...
(Date:12/22/2014)... December 22, 2014 TheHardwareCity.com now stocks ... with many useful features. Customers of the large online ... the new gloves delivered to their home or workplace ... hand tools that incorporate heavy duty magnets, which make ... allows workers to store metal parts on the back ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... in the international research consortium named MetaHit, scientists from ... an individual,s intestinal bacteria flora, regardless of nationality, gender ... of intestinal bacteria flora is hypothesised to have an ... and medicine absorbed through the gastro-intestinal tract. The results ...
... , WEDNESDAY, April 20 (HealthDay News) -- Poor ... more likely than others to cut back on health ... to a new study. Conducted by the RAND ... earlier studies, which found that so-called "medically vulnerable" people ...
... Queen,s University professor Kate Harkness has found that a ... substantially increases the risk of depression in adolescence by ... Adolescents with a history of maltreatment and a mild ... of the stress hormone cortisol than is normal in ...
... Men are more likely to see issues in black-and-white, whereas women ... contends. British researchers asked 113 volunteers to judge how 50 ... The objects and categories were highly likely to stimulate debate or ... a tool? Men were found to be more likely to ...
... School of Medicine researcher has developed a potential ... prevalent sexually transmitted disease and the leading cause ... Ph.D., professor of immunology and microbiology, internal medicine ... demonstrated a vaccine effect to inoculate against Chlamydia ...
... of severe traumatic brain injury (TBI), the U.S. Department ... this type of injury receive adequate protein and calories ... weeks of treatment, says a new report from the ... severely brain-injured patients shows that providing energy and protein ...
Cached Medicine News:Health News:What's your intestinal bacteria type? 2Health News:High-Deductible Health Plans Bring Equal Savings to All: Study 2Health News:WSU files for patent on researcher's vaccine technology for chlamydia 2Health News:WSU files for patent on researcher's vaccine technology for chlamydia 3Health News:WSU files for patent on researcher's vaccine technology for chlamydia 4Health News:Protein and calories can help lessen effects of severe traumatic brain injury 2
For the direct colorimetric determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
For the quantitative determination of uric acid in serum....
For the quantitative determination of uric acid in serum....
Medicine Products: